Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
15.51
+0.11 (0.71%)
At close: Oct 11, 2024, 4:00 PM
15.50
-0.01 (-0.06%)
After-hours: Oct 11, 2024, 4:43 PM EDT
Neumora Therapeutics Employees
Neumora Therapeutics had 124 employees as of December 31, 2023. The number of employees increased by 30 or 31.91% compared to the previous year.
Employees
124
Change (1Y)
30
Growth (1Y)
31.91%
Revenue / Employee
n/a
Profits / Employee
-$2,211,113
Market Cap
2.48B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Dec 31, 2021 | 88 | 35 | 66.04% |
| Dec 31, 2020 | 53 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BrightSpring Health Services | 35,000 |
| Concentra Group Holdings Parent | 9,020 |
| Tandem Diabetes Care | 2,400 |
| Zai Lab | 2,175 |
| Inari Medical | 1,300 |
| ImmunityBio | 628 |
| ACADIA Pharmaceuticals | 598 |
| Agios Pharmaceuticals | 386 |
NMRA News
- 2 months ago - Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - GlobeNewsWire
- 4 months ago - Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation - GlobeNewsWire
- 5 months ago - Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression - GlobeNewsWire
- 5 months ago - Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Neumora's early-stage schizophrenia drug study put on hold - Reuters
- 6 months ago - Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study - GlobeNewsWire
- 7 months ago - Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days - GlobeNewsWire
- 7 months ago - Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire